NCT01655316

Brief Summary

PSVT is a common rhythm disorder in emergency department which can be recurrent in some cases. Intravenous Adenosine is the drug of choice in PSVT control in acute settings but is a very short acting agent. Providing a complementary medication to decrease the rate of recurrence of PSVT after its initial control will be promising. This study evaluates the role of the oral Verapamil in recurrence control of PSVT in emergency situations.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Oct 2010

Shorter than P25 for phase_4

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2010

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2011

Completed
12 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 1, 2012

Completed
Last Updated

November 14, 2012

Status Verified

November 1, 2012

Enrollment Period

10 months

First QC Date

July 30, 2012

Last Update Submit

November 12, 2012

Conditions

Paroxysmal Supraventricular Tachycardia

Outcome Measures

Primary Outcomes (1)

  • Recurrence Control

    2 hours

Study Arms (1)

Verapamil

EXPERIMENTAL

40 mg Verapamil Per Oral

Drug: Verapamil

Interventions

VerapamilDRUG
Verapamil

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age\>18 years old
  • PSVT on emergency department presentation

You may not qualify if:

  • Instability in hemodynamic status
  • Allergy to Verapamil

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Tachycardia, Ventricular

Interventions

Verapamil

Condition Hierarchy (Ancestors)

TachycardiaArrhythmias, CardiacHeart DiseasesCardiovascular DiseasesCardiac Conduction System DiseasePathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PhenethylaminesEthylaminesAminesOrganic Chemicals

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NA
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2012

First Posted

August 1, 2012

Study Start

October 1, 2010

Primary Completion

August 1, 2011

Study Completion

August 1, 2011

Last Updated

November 14, 2012

Record last verified: 2012-11